149 related articles for article (PubMed ID: 22169769)
1. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
3. ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Portelinha A; Thompson S; Smith RA; Da Silva Ferreira M; Asgari Z; Knezevic A; Seshan V; de Stanchina E; Gupta S; Denis L; Younes A; Reddy S
Cell Rep Med; 2021 Jul; 2(7):100350. PubMed ID: 34337566
[TBL] [Abstract][Full Text] [Related]
4. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
Ring KL; Yates MS; Schmandt R; Onstad M; Zhang Q; Celestino J; Kwan SY; Lu KH
Int J Gynecol Cancer; 2017 Jun; 27(5):854-862. PubMed ID: 28498246
[TBL] [Abstract][Full Text] [Related]
5. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action.
McFarland JM; Paolella BR; Warren A; Geiger-Schuller K; Shibue T; Rothberg M; Kuksenko O; Colgan WN; Jones A; Chambers E; Dionne D; Bender S; Wolpin BM; Ghandi M; Tirosh I; Rozenblatt-Rosen O; Roth JA; Golub TR; Regev A; Aguirre AJ; Vazquez F; Tsherniak A
Nat Commun; 2020 Aug; 11(1):4296. PubMed ID: 32855387
[TBL] [Abstract][Full Text] [Related]
7. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Way GP; Sanchez-Vega F; La K; Armenia J; Chatila WK; Luna A; Sander C; Cherniack AD; Mina M; Ciriello G; Schultz N; ; Sanchez Y; Greene CS
Cell Rep; 2018 Apr; 23(1):172-180.e3. PubMed ID: 29617658
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?
Goldberg RM
Oncologist; 2015 Dec; 20(12):1448-56. PubMed ID: 26512044
[TBL] [Abstract][Full Text] [Related]
9. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
11. Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.
Lange F; Franz B; Maletzki C; Linnebacher M; Hühns M; Jaster R
Biomed Res Int; 2014; 2014():568693. PubMed ID: 25309914
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
14. MEK and the inhibitors: from bench to bedside.
Akinleye A; Furqan M; Mukhi N; Ravella P; Liu D
J Hematol Oncol; 2013 Apr; 6():27. PubMed ID: 23587417
[TBL] [Abstract][Full Text] [Related]
15. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
16. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Hatzivassiliou G; Haling JR; Chen H; Song K; Price S; Heald R; Hewitt JF; Zak M; Peck A; Orr C; Merchant M; Hoeflich KP; Chan J; Luoh SM; Anderson DJ; Ludlam MJ; Wiesmann C; Ultsch M; Friedman LS; Malek S; Belvin M
Nature; 2013 Sep; 501(7466):232-6. PubMed ID: 23934108
[TBL] [Abstract][Full Text] [Related]
19. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
20. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]